BioNTech (Mfg Services) vs FUJIFILM Diosynth Biotechnologies: CDMO Comparison

How does BioNTech (Mfg Services) compare to FUJIFILM Diosynth Biotechnologies for mRNA/LNP manufacturing?

As of Aug 2026, BioNTech (Mfg Services): no FDA inspections on file, 8 EMA/MHRA GMP certificates. Signal Score 82.1. FUJIFILM Diosynth Biotechnologies: no FDA inspections on file, 35 EMA/MHRA GMP certificates. Signal Score 86.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Mainz, DE · Marburg, DE
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
8
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
28
Capacity
—
Modalities
mRNA
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
87/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
29
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Key differences

  • FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (29 active certificates vs 8) — stronger EU footprint.
  • FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; BioNTech (Mfg Services) does not.
  • BioNTech (Mfg Services) appears as a manufacturing partner on more matched clinical programs (28 vs 0) — a broader sponsor book.

On a 13-modality CDMO landscape, both BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies qualify as mRNA/LNP manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for mRNA/LNP programs in this comparison.

What to evaluate for mRNA/LNP programs

Both BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

See all mRNA/LNP CDMOs ranked by Signal Score →

Frequently asked: BioNTech (Mfg Services) vs FUJIFILM Diosynth Biotechnologies

How does BioNTech (Mfg Services) compare to FUJIFILM Diosynth Biotechnologies for mRNA/LNP manufacturing?

On CDMO Signal's composite Signal Score, BioNTech (Mfg Services) is 82/100 and FUJIFILM Diosynth Biotechnologies is 87/100; European coverage is 8 active EMA+MHRA certificates for BioNTech (Mfg Services) vs 35 for FUJIFILM Diosynth Biotechnologies. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

How do BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies compare on European GMP coverage?

BioNTech (Mfg Services) holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — BioNTech (Mfg Services) or FUJIFILM Diosynth Biotechnologies?

BioNTech (Mfg Services) is matched to 28 ClinicalTrials.gov records as a manufacturing partner; FUJIFILM Diosynth Biotechnologies is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for mRNA/LNP manufacturing — BioNTech (Mfg Services) or FUJIFILM Diosynth Biotechnologies?

Both BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

BioNTech (Mfg Services) carries a Signal Score of 82/100 and FUJIFILM Diosynth Biotechnologies carries 87/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating BioNTech (Mfg Services) and FUJIFILM Diosynth Biotechnologies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.